within Pharmacolibrary.Drugs.N_NervousSystem.N02C_AntimigrainePreparations.N02CD01_Erenumab;

model Erenumab
  extends Pharmacolibrary.Drugs.ATC.N.N02CD01;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>N02CD01</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Erenumab is a human monoclonal antibody that targets the calcitonin gene-related peptide (CGRP) receptor. It is approved for the preventive treatment of migraine in adults.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult subjects following subcutaneous administration.</p><h4>References</h4><ol><li><p>Shen, Q, et al., &amp; Wang, Z (2022). Pharmacokinetics and Safety of Erenumab after a Single Subcutaneous Injection Dose in Healthy Chinese Subjects. <i>Clinical drug investigation</i> 42(7) 623–630. DOI:<a href=&quot;https://doi.org/10.1007/s40261-022-01171-5&quot;>10.1007/s40261-022-01171-5</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35727536/&quot;>https://pubmed.ncbi.nlm.nih.gov/35727536</a></p></li><li><p>Shen, Q, et al., &amp; Wang, Z (2023). Correction: Pharmacokinetics and Safety of Erenumab after a Single Subcutaneous Injection Dose in Healthy Chinese Subjects. <i>Clinical drug investigation</i> 43(12) 973–974. DOI:<a href=&quot;https://doi.org/10.1007/s40261-023-01321-3&quot;>10.1007/s40261-023-01321-3</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37991687/&quot;>https://pubmed.ncbi.nlm.nih.gov/37991687</a></p></li><li><p>Bussiere, JL, et al., &amp; Monticello, TM (2019). Nonclinical safety evaluation of erenumab, a CGRP receptor inhibitor for the prevention of migraine. <i>Regulatory toxicology and pharmacology : RTP</i> 106 224–238. DOI:<a href=&quot;https://doi.org/10.1016/j.yrtph.2019.05.013&quot;>10.1016/j.yrtph.2019.05.013</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31085251/&quot;>https://pubmed.ncbi.nlm.nih.gov/31085251</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Erenumab;
